
The Three Biggest EHS Blind Spots in the Pharmaceutical Sector
Pharmaceutical companies tend to under-invest in three critical EHS areas that quietly drive disproportionate regulatory risk, cost, and reputational exposure: hazardous waste and emissions, highly potent and hazardous drug handling, and contractor and construction safety. These blind spots usually sit between functions (EHS, QA, engineering, procurement), so no single owner sees the full risk picture until an audit finding or incident forces attention.









